Eli Lil­ly high­lights key R&D cat­a­lysts for 2018; Ver­nalis and Dai­ichi Sankyo work to­geth­er on can­cer tar­gets

→ Eli Lil­ly has a few key R&D cat­a­lysts built in to its 2018 fore­cast, out to­day. Hold­ing the line on an R&D bud­get that runs just north of the $5 bil­lion mark, Lil­ly says they ex­pect a reg­u­la­to­ry de­ci­sion on baric­i­tinib for rheuma­toid arthri­tis — af­ter the FDA walked back a re­quire­ment on a new study — as well as the CGRP drug gal­canezum­ab and a shot at a new in­di­ca­tion for pso­ri­at­ic arthri­tis for Taltz.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.